HOUSE 501118th CongressReferred to the House Committee on the Judiciary.

Honoring the men and women of the Drug Enforcement Administration on the 50th anniversary of the agency.

Last Action: 6/13/2023

Actions

2023-05-17Placed on the Union Calendar, Calendar No. 46.
2023-05-17Committee on the Judiciary discharged.
2023-05-17Committee on the Judiciary discharged.
2023-05-17Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-66, Part I.
2023-05-17Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-66, Part I.
2023-03-24Ordered to be Reported (Amended) by the Yeas and Nays: 44 - 0.
2023-03-24Committee Consideration and Mark-up Session Held.
2023-03-23Committee Consideration and Mark-up Session Held.
2023-03-08Forwarded by Subcommittee to Full Committee by the Yeas and Nays: 28 - 0 .
2023-03-08Subcommittee Consideration and Mark-up Session Held.
2023-01-25Referred to the Subcommittee on Health.
2023-01-25Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2023-01-25Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2023-01-25Introduced in House
2023-01-25Introduced in House

CRS Summary

As of 2023-01-25 (00)

Block, Report, And Suspend Suspicious Shipments Act

This bill creates additional requirements for drug manufacturers and distributors who discover a suspicious order or series of suspicious orders for controlled substances.

Currently, a manufacturer or distributor must report a suspicious order or series of suspicious orders to the Drug Enforcement Administration (DEA). This bill also requires a manufacturer or distributor to exercise due diligence and decline to fill the order. However, if the manufacturer or distributor resolves all of the indicators giving rise to the suspicious order or series of suspicious orders, then the bill allows the manufacturer or distributor to fill the order and choose not to report it to the DEA.

A violation is subject to civil and criminal penalties under the Controlled Substances Act.

The DEA must issue regulations specifying the indicators that give rise to a suspicious order.

Cosponsors (7)

Debbie Dingell (D-MI)
Ashley Hinson (R-IA)
Susie Lee (D-NV)
Jill Tokuda (D-HI)
Juan Ciscomani (R-AZ)
Kim Schrier (D-WA)
Marcus Molinaro (R-NY)

Subjects

Administrative law and regulatory procedures
Department of Justice
Drug trafficking and controlled substances
Prescription drugs
Retail and wholesale trades

Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.